{
    "nct_id": "NCT04319198",
    "official_title": "Open-label Rollover Study to Evaluate Long-Term Safety in Subjects With Metastatic Solid Tumors That Are Benefiting From Continuation of Therapy With Sacituzumab Govitecan",
    "inclusion_criteria": "* Receiving ongoing treatment with sacituzumab govitecan in a Gilead (previously Immunomedics)-sponsored parent study\n* Continuing to receive clinical benefit from sacituzumab govitecan-hziy therapy\n\nKey\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Females who are pregnant or lactating\n* Initiated therapy with another cancer therapeutic agent since receiving last dose of study drug on the parent study in which they participated\n* Experienced a toxicity from sacituzumab govitecan-hziy that resulted in permanent discontinuation of therapy\n* Have other concurrent medical or psychiatric conditions that, in the Investigator's opinion, may be likely to confound study interpretation or prevent completion of study procedures and follow-up examinations.\n\nNote: Other protocol defined Inclusion/Exclusion criteria may apply.",
    "miscellaneous_criteria": "Key"
}